Covid Reference

Page 72

72

|

CovidReference.com

Ecology of SARS-CoV-2 SARS-CoV-2 is present at the highest concentrations in the respiratory tract early in disease and then increases in the lower respiratory tract (Zhu N 2020, Wang 2020, Huang 2020, Wölfel 2020). The virus has also been found, albeit at low levels, in the kidney, liver, heart, brain, and blood (Puelles 2020). Outside the human body, the virus is more stable at low temperature and low humidity conditions, whereas warmer temperatures and higher humidity shorten the half-life (Matson 2020). It has also been shown to be detectable as an aerosol (in the air) for up to three hours, up to 24 hours on cardboard and up to two to three days on plastic and stainless steel (van Doremalen 2020). As expected, viral RNA was more likely to be found in areas immediately occupied by COVID-19 patients than in other hospital areas (Zhou J 2020). Another study documented contamination of toilets (toilet bowl, sink, and door handle) and air outlet fans (Ong SWX 2020). This is in line with the experience from MERS where many environmental surfaces of patients’ rooms, including points frequently touched by patients or healthcare workers, were contaminated by MERS-CoV (Bin 2016).

Person-to-person transmission Person-to-person transmission of SARS-CoV-2 was established within weeks of identification of the first cases (Chan JF 2020, Rothe 2020). Shortly after, it was suggested that asymptomatic individuals would probably account for a substantial proportion of all SARS-CoV-2 transmissions (Nishiura 2020, Li 2020). Viral load can be high 2-3 days before the onset of symptoms and almost half of all secondary infections are supposed to be caused by presymptomatic patients (He 2020). A key factor in the transmissibility of SARS-CoV-2 is the high level of viral shedding in the upper respiratory tract (Wolfel 2020), even among paucisymptomatic patients. Pharyngeal virus shedding is very high during the first week of symptoms, with a peak at > 7 x 108 RNA copies per throat swab on day 4. Infectious virus was readily isolated from samples derived from the throat or lung. That distinguishes it from SARS-CoV, where replication occured mainly in the lower respiratory tract (Gandhi 2020); SARS-CoV and MERS-CoV infect intrapulmonary epithelial cells more than cells of the upper airways (Cheng PK 2004, Hui 2018). The shedding of viral RNA from sputum appears to outlast the end of symptoms and seroconversion is not always followed by a rapid decline in viral load (Wolfel 2020). This contrasts with influenza where persons with asymptomatic disease generally have lower quantitative viral loads in secretions Kamps – Hoffmann


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

References

1hr
pages 497-554

Management

10min
pages 491-496

Diagnosis and classification

11min
pages 484-490

Transplantation

4min
pages 472-473

Transmission

4min
pages 482-483

Pathophysiology and immunopathology

4min
pages 480-481

Natural course and risk factors for complications

2min
page 479

Epidemiology of COVID-19 in children

2min
page 478

Cancer

8min
pages 468-471

Immunosuppression (other than HIV

3min
pages 466-467

HIV infection

6min
pages 463-465

COPD and smoking

4min
pages 461-462

Hypertension and cardiovascular co-morbidities

14min
pages 452-458

Diabetes mellitus

4min
pages 459-460

References

6min
pages 447-451

Special situations in severe COVID-19

3min
pages 445-446

References

25min
pages 429-440

Spotlight: The situation in a German COVID-19 hospital

4min
pages 443-444

Outlook and Recommendations

1min
page 428

4. Immunomodulators

19min
pages 415-424

Other treatments for COVID-19 (with unknown or unproven mechanisms of action

5min
pages 425-427

3. Monoclonal Antibodies and Convalescent Plasma

13min
pages 408-414

2. Various antiviral agents

5min
pages 405-407

1. Inhibitors of the viral RNA synthesis

11min
pages 399-404

Monitoring, treatment options

3min
pages 391-392

Studies with objectifiable tests

3min
pages 389-390

Reactivations, reinfections

2min
page 366

Outcome

27min
pages 352-365

Clinical classification

1min
page 351

Laboratory findings

6min
pages 347-350

References

21min
pages 324-332

Asymptomatic cases

4min
pages 334-335

Radiology

6min
pages 321-323

Incubation period

1min
page 333

Symptoms

21min
pages 336-346

Diagnosis

36min
pages 303-320

References

55min
pages 277-302

Outlook

5min
pages 272-276

Single Vaccines

24min
pages 247-261

Coming vaccines

8min
pages 267-271

Special Topics

9min
pages 241-246

Approved Vaccines

2min
pages 223-224

References

21min
pages 211-222

Outlook

1min
page 210

Transmission

1min
page 187

Epidemiology

11min
pages 175-186

Summary – 13 February

1min
page 173

Genomic Structure and Variation

4min
pages 164-166

References

8min
pages 167-172

Origin and Evolution

4min
pages 158-159

Introduction

1min
page 174

History

4min
pages 154-155

References

20min
pages 136-152

Conclusion

1min
page 135

Introduction

31min
pages 117-133

Containment or mitigation of COVID-19?

1min
page 134

References

40min
pages 99-116

Outlook

1min
page 98

Prevention

3min
pages 96-97

End of Quarantine

1min
page 95

Transmission Event

26min
pages 82-94

References

31min
pages 54-68

Summary

1min
page 69

Routes of Transmission

16min
pages 73-81

Outlook

3min
pages 52-53

The 2020 Lockdowns

7min
pages 48-51

Person-to-person transmission

2min
page 72

Special Aspects of the Pandemic

15min
pages 38-46

The SARS-CoV-2 pandemic: Past and Future

2min
page 47
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.